CareFirst BCBS Medical Policy Updates – July 2018

Click here to view the CareFirst Blue Cross Blue Shield Medical Policy Updates »

July 2018 CareFirst BCBS Medical Policy Updates:

• Archived Assisted Reproductive Technology (ART) Artificial Insemination (AI) Intrauterine Insemination (IUI)
• Archived Circulating Tumor Cell Detection in Management of Cancer Patients
• Archived Human Growth Hormone (HGH) Therapy
• Assisted Reproductive Technology (ART) Procedures In Vitro Fertilization (IVF) Gamete Intrafallopian Transfer (GIFT) Zygote Intrafallopian Transfer (ZIFT)
• Autism Spectrum Disorders (Virginia Mandate)
• Axicabtagene Ciloleucel (YescartaTM)
• Botulinum Toxin (Botox)
• Circulating Tumor DNA and Circulating Tumor Cell Detection in Management of Cancer Patients (liquid biopsy)
• Colony Stimulating Factors (CVS)
• Coronary Computed Tomography Angiography and Selective Noninvasive Fractional Flow Reserve
• Electroconvulsive Therapy
• Global Maternity Care
• Habilitative Services (MD and DC Mandates)
• Human Growth Hormone Therapy
• Intravenous Immune Globulin (IVIG) Therapy
• Pharmacogenomic Assay for the Management of Major Depressive Disorder (GeneSight Psychotropic)
• Psychological Testing
• Repository Corticotropin Injection
• Transcranial Magnetic Stimulation for Treatment of Depression and Other Psychiatric Neurologic Disorders
• Urine Exosome Assay to Predict High-grade Prostate Cancer at Initial Biopsy ExoDx Prostate (IntelliScore)
• Attention Deficit Disorder (ADD) with or without Hyperactivity
• Cavernous Nerve Stimulation Device
• Gene Expression Assays for Managing Prostate Cancer
• Handheld Radiofrequency Spectroscopy for Intraoperative Margin Assessment During Breast Conserving Surgery
• Implanted and Semi-implanted Hearing Assist Devices
• Interspinous Vertebral Decompression Implantation for Spinal Stenosis
• Lymphedema Therapy (Complex Decongestive Therapy)
• Peroral Endoscopic Myotomy (POEM) for Esophageal Achalasia
• Prostatic Urethral Lift for Benign Prostatic Hypertrophy
• Steroid-eluting Implants for Sinus Surgery
• Thermography and Temperature Gradient Studies
• Transcatheter Closure of the Left Atrial Appendage
• Transcranial Magnetic Stimulation for Treatment of Depression and Other Psychiatric Neurologic Disorders
• Xofigo (radium-223 dichloride) Injection for Treatment of Prostate Cancer
• Zoster Vaccine (Oka Merck) (Zostavax) (GlaxoSmithKline) Shingrix

Click here to view the CareFirst Blue Cross Blue Shield Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While Payers typically update medical policies annually, there are many reasons why a Payer might review or update a policy. When reviews occur out of cycle, they may go unnoticed. Policy Alerts keeps you informed of upcoming and unexpected coverage changes affecting your product. Quickly understanding the changes Payers make can help you adjust reimbursement strategies impacting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on Payer decisions in real-time. Whenever changes occur, email notifications containing a summary of those changes are delivered to your inbox. Clients can access detailed coverage reports and medical policies on the interactive Dashboard portal. Save time and keep focused on the important Payer medical policy reviews and coverage decisions affecting your product!

Policy Alerts takes a client-focused hands-on approach and works hard to provide our customers with helpful insights and actionable analytics over raw data. We understand what our clients need and we are dedicated to making sure we provide timely, accurate and always up-to-date reports that can be used to implement and support a successful reimbursement strategy.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.